IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2026

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

IL3 CAR T-cells

Each subject receive IL3 CAR T-cells by intravenous infusion

Trial Locations (1)

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER